ClinicalTrials.gg
RecruitingNCT07074496Updated Jun 17, 2026

Efficacy, Safety, and Pharmacokinetics of ThisCART19A Combined With Olverembatinib in Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.

An Early Phase 1 interventional study of ThisCART19A and Fludarabine in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia, sponsored by The First Affiliated Hospital of Soochow University. Recruiting at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-17.

Sponsored by The First Affiliated Hospital of Soochow University · Early Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 12 studies in Philadelphia Chromosome with a site in China — 2 open to participants now, 4 under way, 2 of them phase 3. Philadelphia Chromosome · China.

Planned enrollment
8th of 11
20 · median 67
Started
2024
with 1 other
Phase 1
Only one
of the 12
Registered
12th of 12
by date
Lead sponsor
2 of 12
The First Affiliated Hospital of Soochow University

Among the 12 studies in Philadelphia Chromosome with a site in China, this one is the 8th largest by planned enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2024, is the only one in phase 1, and was the 12th registered.

Philadelphia Chromosome

52 studies on the registry are indexed under Philadelphia Chromosome; 13 are open to participants now.

Browse Philadelphia Chromosome studies →

Open to participants now

2 of the 12 studies in Philadelphia Chromosome with a site in China are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 10 Philadelphia Chromosome studies recruiting now, 5 (50%) set no upper age limit and 5 (50%) stop at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Philadelphia Chromosome with a site in China, or all of them as a file.
02

Study summary

This is an Open, Prospective, Single-arm Study, which is designed to evaluate the efficacy, safety and pharmacokinetics of ThisCART19A Combined With Olverembatinib for the treatment of Newly Diagnosed Ph-positive lymphoblastic leukemia.

Read the detailed description

To evaluate the efficacy, safety and pharmacokinetics of ThisCART19A Combined With Olverembatinib for the treatment of Ph-positive lymphoblastic leukemia. Newly diagnosed Ph-positive patients will be given VP chemotherapy for induction treatment until the leukocyte count is less than 10×109/L. Then chemotherapy regimen of fludarabine and cyclophosphamide followed by a infusion of ThisCART19A. These patients will combination with Olverembatinib as maintenance therapy based on the hematologic complete remission of leukemia after 4 weeks of treatment.

Patients could receive an additional infusion of ThisCART19A if they achieved initial benefit and subsequently minimal residual disease positive (defined as Flow-cytometric MRD≥0.1%) during maintenance treatment. Additionally, a subset of patients which achieved complete molecular remission over 6 month were eligible for a second planned infusion as a consolidation therapy .

During the treatment, lumbar puncture combined with sheath injection will be performed to prevent central nervous system leukemia (CSNL). If CNSL occurs at the time of admission, patients should receive regular conventional lumbar puncture and sheath injection for treating CNSL.

During the treatment, each subject will be evaluated regularly, including hematological response, FCM-MRD, cytogenetic response and molecular remission rate, as well as adverse events. EFS and OS will be followed up for 2 years.

03

Conditions studied

  • Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or non-pregnant, non-lactating female patients who are 18 years of age or older.
  2. Newly diagnosed Philadelphia chromosome-positive (Ph+) or BCR-ABL1-positive ALL, as defined by the 2016-WHO criteria. Participants should not be treated with any kind of TKIs or chemotherapy.
  3. (ECOG) performance status ≤ 2, and expected survival period ≥ 3 months.
  4. Organ function as indicated by the following laboratory indicators must be met:

1. (ALT) ≤ 5× (ULN), aspartate aminotransferase (AST) ≤ 5×ULN; 2. Total \<2×ULN; 3. 24-hour calculated >30 mL/min; 4. SpO2≥92%; 5. Cardiac (EF)≥40%;

Exclusion criteria

Exclusion Criteria:

  1. Active virus (defined as serum HBV-DNA ≥ 2000 IU/mL), virus (HCV), (HIV) or active syphilis infection prior to enrollment. (Subjects with HBV-DNA \< 2000 IU/mL can be enrolled, but should be administered antiviral drugs such as entecavir and tenofovir with relative clinical indicators monitored simultaneously during the treatment.) ;
  2. Uncontrolled active infection;
  3. Patients who are currently suffering from active disease or a history of autoimmune disease potentially involving the CNS;
  4. Patients who have any history of heart or vascular disease, such as hypertension (systolic blood pressure(HBP) > 140mmHg and/or diastolic blood pressure > 90mmHg);
  5. Cardiac ultrasonography indicates that pulmonary artery systolic blood pressure is >50 mmHg; or there are clinical symptoms related to pulmonary arterial hypertension;
  6. Patients who suffer from severe bleeding disorders unrelated to Ph+ ALL;
  7. Patients who have any other malignant tumors that require treatment;
  8. Patients who have severe hypertriglyceridemia (triglyceride ≥ 5.6mmol/L);
  9. Patients who are pregnant, planning to become pregnant or breastfeeding;
  10. Patients who underwent major surgery (except for minor surgery such as catheter placement or bone marrow ) within 14 days before the first drug;
  11. Patients who may not be able to complete all study visits or procedures required by the study protocol, including follow-up visits, and/or fail to comply with all required study procedures;
  12. Patients who suffer from any condition or illness that, in the opinion of the Investigator, would compromise patient safety or interfere with the evaluation of the safety of the research drug.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Treatment Group

    ThisCART19A cells infusion, Given intravenously,Combined With Olverembatinib, Given PO

    Drug: ThisCART19A · Drug: Fludarabine · Drug: Cyclophosphamide · Drug: Olverembatinib

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants with Complete Molecular Remission

    Will be estimated along with the 95% credible intervals. Complete molecular response (CMR) was defined as the absence of a detectable BCR-ABL1 transcript with a sensitivity of 0.01%.

    Time frame: 3 months

  2. Incidence of adverse events (AEs)

    Will be graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5.0. The proportion of patients with AEs will be estimated, along with the Bayesian 95% credible interval.

    Time frame: 2 years

Secondary outcomes

  1. Objective Response Rate (ORR)

    Will be estimated along with the 95% credible intervals. ORR is defined by Complete Remission (CR)+ CR with incomplete marrow recovery (CRi) .

    Time frame: 2 years

  2. Duration of Complete Molecular Remission

    Will be estimated along with the 95% credible intervals.

    Time frame: From the date of acquisition of complete molecular remission until the date of loss of complete molecular remission, assessed up to 2 years.

  3. Event-free survival (EFS)

    The Kaplan-Meier method will be used to assess EFS probabilities.

    Time frame: From the first day of treatment until any failure (resistant disease, relapse, or death), assessed up to 2 years

  4. Overall survival (OS)

    The Kaplan-Meier method will be used to assess OS probabilities.

    Time frame: From the first day of treatment to time of death from any cause, assessed up 2 years

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2024 to primary completion in Nov 2025, 22 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2024
First posted
Jul 20, 2025
StartActual
Jan 1, 2024
Primary completionActual
Nov 15, 2025
CompletionEst.
Jul 1, 2028
Last update
Jun 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07074496
Collaborators
Fundamenta Therapeutics, Ltd.
Responsible party
Sponsor
First posted
Jul 20, 2025
Start date
Jan 1, 2024
Primary completion
Nov 15, 2025
Completion
Jul 1, 2028 (estimated)
Last update
Jun 17, 2026

Study contacts

Suning Chen, professor
Contact
chensuning@sina.com
+86-13814881746

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Allogeneic Anti-CD19 T-cells ThisCART19A · Olverembatinib

Start the discussion